2025 Q3 -tulosraportti
65 päivää sitten1 t 2 min
0,0723 USD/osake
Viimeisin osinko
Tarjoustasot
Määrä
Osto
200
Myynti
Määrä
2 742
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 28.1. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 5.11.2025 | |
| 2025 Q2 -tulosraportti | 30.7.2025 | |
| 2025 Q1 -tulosraportti | 7.5.2025 | |
| 2024 Q4 -tulosraportti | 29.1.2025 | |
| 2024 Q3 -tulosraportti | 6.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenWhat just happened there with the share price, no news and then just 5% up?
·1 päivä sitten · Muokattuit is probably fundamentally a reaction to them having gradually cleared up the pending lawsuits and superfluous expenses have been cut so they can look forward..... with a consequently improved credit rating=lower interest rates/better borrowing opportunities....with the following better price targets that are now coming thick and fast... I entered at a price of approx 31 but should just have held from a price of approx 8 which I originally bought at.....
·1 päivä sittenYes, there are several things that apply. It probably also matters that one is moving away from only producing low-margin generic medicine to branded products, with significantly higher margins, but of course, deleveraging of the debt is extremely important. At some point, one could end up with something as rare as a debt-free pharma company with "own" products.
·24.12.2025Does the new credit rating have an influence on TEVA's debt?·24.12.2025How is profit/revenue compared to the 2010s when the share price was much higher?
·15.12.2025Now we are waiting for January 28. The debt is not falling quite as fast as in Kaare's time, but it is still generally decreasing, even though growth costs a bit. That the Dollar is falling can be an advantage in the next redemptions. https://s24.q4cdn.com/720828402/files/doc_financials/2025/q3/Teva-Factsheet-Q3-2025.pdf I am keeping it, and agree with the analysts.·19.12.2025Agreed, but without being 100% sure, Teva has a very large sales volume in US, so they have large USD revenues, so it's 1:1, but then it's also good to have EUR revenues because there are some large loan redemptions in 2027-2028. I myself am very, as in very, heavily invested in Teva and see the long-term potential, and my prophecy a few weeks ago about a price of USD 30 by New Year's or at the latest by the Q4 2025 presentation, Teva reached that very quickly. Q4 is usually the best quarter of the year so I have no doubt that this will also be the case this time. I follow the conference calls, and they are fishing for significant future prospects, so I believe the big fish are hungry, and that is also what has driven the price up, so I would not be surprised if there is a USD 5+ jump in Q1 2026, and a 20-30% price increase in 2026 I certainly think is within the scope.- ·11.12.2025I think it's slowly but surely going the right way for a long time now, as they'll soon have shaved off the debt... great! I got in at 12.30, so I've been super lucky!
·14.12.2025And I just bought, so I hope to feel lucky soon 🤣 though a small amount and they'll just be left to stand 😜
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
65 päivää sitten1 t 2 min
0,0723 USD/osake
Viimeisin osinko
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenWhat just happened there with the share price, no news and then just 5% up?·1 päivä sitten · Muokattuit is probably fundamentally a reaction to them having gradually cleared up the pending lawsuits and superfluous expenses have been cut so they can look forward..... with a consequently improved credit rating=lower interest rates/better borrowing opportunities....with the following better price targets that are now coming thick and fast... I entered at a price of approx 31 but should just have held from a price of approx 8 which I originally bought at.....·1 päivä sittenYes, there are several things that apply. It probably also matters that one is moving away from only producing low-margin generic medicine to branded products, with significantly higher margins, but of course, deleveraging of the debt is extremely important. At some point, one could end up with something as rare as a debt-free pharma company with "own" products.
- ·24.12.2025Does the new credit rating have an influence on TEVA's debt?·24.12.2025How is profit/revenue compared to the 2010s when the share price was much higher?
- ·15.12.2025Now we are waiting for January 28. The debt is not falling quite as fast as in Kaare's time, but it is still generally decreasing, even though growth costs a bit. That the Dollar is falling can be an advantage in the next redemptions. https://s24.q4cdn.com/720828402/files/doc_financials/2025/q3/Teva-Factsheet-Q3-2025.pdf I am keeping it, and agree with the analysts.·19.12.2025Agreed, but without being 100% sure, Teva has a very large sales volume in US, so they have large USD revenues, so it's 1:1, but then it's also good to have EUR revenues because there are some large loan redemptions in 2027-2028. I myself am very, as in very, heavily invested in Teva and see the long-term potential, and my prophecy a few weeks ago about a price of USD 30 by New Year's or at the latest by the Q4 2025 presentation, Teva reached that very quickly. Q4 is usually the best quarter of the year so I have no doubt that this will also be the case this time. I follow the conference calls, and they are fishing for significant future prospects, so I believe the big fish are hungry, and that is also what has driven the price up, so I would not be surprised if there is a USD 5+ jump in Q1 2026, and a 20-30% price increase in 2026 I certainly think is within the scope.
- ·11.12.2025I think it's slowly but surely going the right way for a long time now, as they'll soon have shaved off the debt... great! I got in at 12.30, so I've been super lucky!·14.12.2025And I just bought, so I hope to feel lucky soon 🤣 though a small amount and they'll just be left to stand 😜
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
200
Myynti
Määrä
2 742
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 28.1. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 5.11.2025 | |
| 2025 Q2 -tulosraportti | 30.7.2025 | |
| 2025 Q1 -tulosraportti | 7.5.2025 | |
| 2024 Q4 -tulosraportti | 29.1.2025 | |
| 2024 Q3 -tulosraportti | 6.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
65 päivää sitten1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 28.1. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 5.11.2025 | |
| 2025 Q2 -tulosraportti | 30.7.2025 | |
| 2025 Q1 -tulosraportti | 7.5.2025 | |
| 2024 Q4 -tulosraportti | 29.1.2025 | |
| 2024 Q3 -tulosraportti | 6.11.2024 |
Datan lähde: Quartr, FactSet
0,0723 USD/osake
Viimeisin osinko
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenWhat just happened there with the share price, no news and then just 5% up?·1 päivä sitten · Muokattuit is probably fundamentally a reaction to them having gradually cleared up the pending lawsuits and superfluous expenses have been cut so they can look forward..... with a consequently improved credit rating=lower interest rates/better borrowing opportunities....with the following better price targets that are now coming thick and fast... I entered at a price of approx 31 but should just have held from a price of approx 8 which I originally bought at.....·1 päivä sittenYes, there are several things that apply. It probably also matters that one is moving away from only producing low-margin generic medicine to branded products, with significantly higher margins, but of course, deleveraging of the debt is extremely important. At some point, one could end up with something as rare as a debt-free pharma company with "own" products.
- ·24.12.2025Does the new credit rating have an influence on TEVA's debt?·24.12.2025How is profit/revenue compared to the 2010s when the share price was much higher?
- ·15.12.2025Now we are waiting for January 28. The debt is not falling quite as fast as in Kaare's time, but it is still generally decreasing, even though growth costs a bit. That the Dollar is falling can be an advantage in the next redemptions. https://s24.q4cdn.com/720828402/files/doc_financials/2025/q3/Teva-Factsheet-Q3-2025.pdf I am keeping it, and agree with the analysts.·19.12.2025Agreed, but without being 100% sure, Teva has a very large sales volume in US, so they have large USD revenues, so it's 1:1, but then it's also good to have EUR revenues because there are some large loan redemptions in 2027-2028. I myself am very, as in very, heavily invested in Teva and see the long-term potential, and my prophecy a few weeks ago about a price of USD 30 by New Year's or at the latest by the Q4 2025 presentation, Teva reached that very quickly. Q4 is usually the best quarter of the year so I have no doubt that this will also be the case this time. I follow the conference calls, and they are fishing for significant future prospects, so I believe the big fish are hungry, and that is also what has driven the price up, so I would not be surprised if there is a USD 5+ jump in Q1 2026, and a 20-30% price increase in 2026 I certainly think is within the scope.
- ·11.12.2025I think it's slowly but surely going the right way for a long time now, as they'll soon have shaved off the debt... great! I got in at 12.30, so I've been super lucky!·14.12.2025And I just bought, so I hope to feel lucky soon 🤣 though a small amount and they'll just be left to stand 😜
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
200
Myynti
Määrä
2 742
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt